Asset Details
Do you wish to reserve the book?
Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour
Do you wish to request the book?
Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rapid target allopurinol concentrations in the hypoxic fetus after maternal administration during labour
2014
Overview
Objective Perinatal hypoxia-induced free radical formation is an important cause of hypoxic-ischaemic encephalopathy and subsequent neurodevelopmental disabilities. Allopurinol reduces the formation of free radicals, which potentially limits hypoxia-induced brain damage. We investigated placental transfer and safety of allopurinol after maternal allopurinol treatment during labour to evaluate its potential role as a neuroprotective agent in suspected fetal hypoxia. Design We used data from a randomised, double-blind multicentre trial comparing maternal allopurinol versus placebo in case of imminent fetal hypoxia (NCT00189007). Patients We studied 58 women in labour at term, with suspected fetal hypoxia prompting immediate delivery, in the intervention arm of the study. Setting Delivery rooms of 11 Dutch hospitals. Intervention 500 mg allopurinol, intravenously to the mother, immediately prior to delivery. Main outcome measures Drug disposition (maternal plasma concentrations, cord blood concentrations) and drug safety (maternal and fetal adverse events). Results Within 5 min after the end of maternal allopurinol infusion, target plasma concentrations of allopurinol of ≥2 mg/L were present in cord blood. Of all analysed cord blood samples, 95% (52/55) had a target allopurinol plasma concentration at the moment of delivery. No adverse events were observed in the neonates. Two mothers had a red and/or painful arm during infusion. Conclusions A dose of 500 mg intravenous allopurinol rapidly crosses the placenta and provides target concentrations in 95% of the fetuses at the moment of delivery, which makes it potentially useful as a neuroprotective agent in perinatology with very little side effects. Trial registration The study is registered in the Dutch Trial Register (NTR1383) and the Clinical Trials protocol registration system (NCT00189007).
Publisher
BMJ Publishing Group,BMJ Publishing Group LTD
Subject
/ Allopurinol - therapeutic use
/ Biological and medical sciences
/ Delivery. Postpartum. Lactation
/ Female
/ Fetal Hypoxia - drug therapy
/ Fetal Hypoxia - prevention & control
/ Fetuses
/ Free Radical Scavengers - pharmacology
/ Free Radical Scavengers - therapeutic use
/ Free Radicals - adverse effects
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Hypoxia
/ Hypoxia-Ischemia, Brain - prevention & control
/ Labor, Obstetric - drug effects
/ Maternal, fetal and perinatal monitoring
/ Maternal-Fetal Exchange - drug effects
/ Neonates
/ Neuroprotective Agents - pharmacology
/ Neuroprotective Agents - therapeutic use
/ Placenta
/ Rodents
/ Studies
